AIMS: Intravenous formulations of busulfan have recently become available. Although busulfan is used frequently in children as part of a myeloablative regimen prior to bone marrow transplantation, pharmacokinetic data on intravenous busulfan in children are scarce. The aim was to investigate intravenous busulfan pharmacokinetics in children and to suggest a limited sampling strategy in order to determine busulfan systemic exposure with the minimum of inconvenience and risk for the patient. METHODS: Plasma pharmacokinetics after the first administration was investigated in six children using nonlinear mixed effect modelling. RESULTS: Pharmacokinetics showed little variability and were described adequately with a one-compartment model (population estimates CL,av=0.29 l h(-1) kg(-1); V,av=0.84 l kg(-1); t(1/2)=1.7-2.8 h). Combined with limited sampling and a Bayesian fitting procedure, the model can adequately estimate the systemic exposure to intravenous busulfan, which in children appears to be at the lower end of the adult range. CONCLUSIONS: Busulfan systemic exposure in children during intravenous administration can be estimated adequately with limited sampling and a Bayesian fitting procedure from a one-compartment model. Intravenous busulfan pharmacokinetics in children should be the subject of more research.
AIMS: Intravenous formulations of busulfan have recently become available. Although busulfan is used frequently in children as part of a myeloablative regimen prior to bone marrow transplantation, pharmacokinetic data on intravenous busulfan in children are scarce. The aim was to investigate intravenous busulfan pharmacokinetics in children and to suggest a limited sampling strategy in order to determine busulfan systemic exposure with the minimum of inconvenience and risk for the patient. METHODS: Plasma pharmacokinetics after the first administration was investigated in six children using nonlinear mixed effect modelling. RESULTS: Pharmacokinetics showed little variability and were described adequately with a one-compartment model (population estimates CL,av=0.29 l h(-1) kg(-1); V,av=0.84 l kg(-1); t(1/2)=1.7-2.8 h). Combined with limited sampling and a Bayesian fitting procedure, the model can adequately estimate the systemic exposure to intravenous busulfan, which in children appears to be at the lower end of the adult range. CONCLUSIONS:Busulfan systemic exposure in children during intravenous administration can be estimated adequately with limited sampling and a Bayesian fitting procedure from a one-compartment model. Intravenous busulfan pharmacokinetics in children should be the subject of more research.
Authors: B S Andersson; J Gajewski; M Donato; S Giralt; V Gian; J Wingard; S Tarantolo; H Fernandez; W W Hu; K Blume; A Kashyap; S J Forman; R E Champlin Journal: Bone Marrow Transplant Date: 2000-05 Impact factor: 5.483
Authors: Z Hassan; P Ljungman; O Ringdén; J Winiarski; C Nilsson; J Aschan; H R Whitley; M Hassan Journal: Bone Marrow Transplant Date: 2001-03 Impact factor: 5.483
Authors: M Hassan; G Oberg; A N Bekassy; J Aschan; H Ehrsson; P Ljungman; G Lönnerholm; B Smedmyr; A Taube; I Wallin Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333
Authors: B S Andersson; T Madden; H T Tran; W W Hu; K G Blume; D S Chow; R E Champlin; W P Vaughan Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: E Olavarria; M Hassan; A Eades; C Nilsson; A Timms; J Matthews; C Craddock; E Kanfer; J Apperley; J Goldman Journal: Leukemia Date: 2000-11 Impact factor: 11.528
Authors: H T Tran; T Madden; D Petropoulos; L L Worth; E A Felix; H A Sprigg-Saenz; M Choroszy; M Danielson; D Przepiorka; K W Chan Journal: Bone Marrow Transplant Date: 2000-09 Impact factor: 5.483
Authors: M Hassan; A Fasth; B Gerritsen; A Haraldsson; Z Syrůcková; H van den Berg; M Sandström; M Karlsson; S Kumlien; J Vossen Journal: Bone Marrow Transplant Date: 1996-11 Impact factor: 5.483
Authors: G Vassal; A Fischer; D Challine; I Boland; F Ledheist; S Lemerle; E Vilmer; C Rahimy; G Souillet; E Gluckman Journal: Blood Date: 1993-08-01 Impact factor: 22.113
Authors: Belén P Solans; Robert Chiesa; Bilyana Doncheva; Helen Prunty; Paul Veys; Iñaki F Trocóniz; Joseph F Standing Journal: Br J Clin Pharmacol Date: 2020-03-03 Impact factor: 4.335
Authors: Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2013-07 Impact factor: 4.335
Authors: Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar Journal: J Clin Pharmacol Date: 2017-12-14 Impact factor: 3.126
Authors: M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac Journal: Bone Marrow Transplant Date: 2015-09-21 Impact factor: 5.483
Authors: Michael Neely; Michael Philippe; Teresa Rushing; Xiaowei Fu; Michael van Guilder; David Bayard; Alan Schumitzky; Nathalie Bleyzac; Sylvain Goutelle Journal: Ther Drug Monit Date: 2016-06 Impact factor: 3.681
Authors: Jurgen B Langenhorst; Jill Boss; Charlotte van Kesteren; Arief Lalmohamed; Jürgen Kuball; Antoine C G Egberts; Jaap Jan Boelens; Alwin D R Huitema; Erik M van Maarseveen Journal: Br J Clin Pharmacol Date: 2020-03-10 Impact factor: 4.335